NBIX - Neurocrine shares fall after mid-stage schizophrenia study results

Neurocrine Biosciences shares slide ([[NBIX]] -6.7%) after announcing that its investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet the primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by the change from baseline on the PANSS NSFS at Day 84.The company said that Luvadaxistat met secondary endpoints of cognitive assessment, which merit further clinical evaluation.The results from the Phase II INTERACT study are being evaluated to determine next steps for development activities.INTERACT is a Phase II, twelve-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study that evaluated the efficacy, safety, tolerability and pharmacokinetics of three dosing levels of luvadaxistat as an adjunctive treatment of adult patients with negative symptoms of schizophrenia.Schizophrenia is a serious and complex syndrome with heterogeneous symptoms that impacts more than 20M people worldwide.

For further details see:

Neurocrine shares fall after mid-stage schizophrenia study results